A Rare Case of Drug-Induced Erectile Dysfunction with Secukinumab Solved After Switch to Ixekizumab in A Psoriatic Patient: A Case Report

Author(s): Stefano Dastoli, Luigi Francesco Iannone, Luigi Bennardo*, Martina Silvestri, Caterina Palleria, Steven Paul Nisticò, Giovambattista De Sarro, Emilio Russo.

Journal Name: Current Drug Safety

Volume 15 , Issue 1 , 2020

Become EABM
Become Reviewer

Abstract:

Background: Psoriasis is a cutaneous inflammatory condition characterized by an altered turnover of keratinocytes leading to scaly patches. Secukinumab and ixekizumab are two biologic drugs inhibiting interleukin-17.

Objective: We report the first case, according to Naranjo score, of a secukinumab-induced erectile dysfunction with severe plaque psoriasis that disappeared after switching to another anti IL17 drug (ixekizumab).

Methods: A 45 years old man experienced erectile dysfunction during treatment with an anti-IL17. The adverse effect appeared after 60 days of treatment with secukinumab and rapidly disappeared after discontinuation of the drug. All necessary urologic exams were carried out. Re-administration of secukinumab, due to the exacerbation of psoriasis, caused the same sexual dysfunction after 60 days.

Results: Switching to ixekizumab lead to a resolution of the erectile dysfunction and a complete skin clearance.

Conclusion: We describe for the first time a sexual dysfunction possibly due to secukinumab and its resolution after the switch to another similar but different drug, highlighting the potential difference between anti-IL17A drugs.

Keywords: Anti-IL17, psoriasis, sexual dysfunction, drug-related side effects, ixekizumab, secukinumab, naranjo Score.

[1]
Greb JE, Goldminz AM, Elder JT, et al. Psoriasis. Nat Rev Dis Primers 2016; 2: 16082.
[http://dx.doi.org/10.1038/nrdp.2016.82] [PMID: 27883001]
[2]
Loos AM, Liu S, Segel C, Ollendorf DA, Pearson SD, Linder JA. Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis. J Am Acad Dermatol 2018; 79(1): 135-144.e7.
[http://dx.doi.org/10.1016/j.jaad.2018.02.027] [PMID: 29438757]
[3]
Campa M, Mansouri B, Warren R, Menter A. A review of biologic therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasis. Dermatol Ther (Heidelb) 2016; 6(1): 1-12.
[http://dx.doi.org/10.1007/s13555-015-0092-3] [PMID: 26714681]
[4]
Antonelli M, Khan MA, Magrey MN. Differential adverse events between TNF-α inhibitors and IL-17 axis inhibitors for the treatment of spondyloarthritis. Curr Treatm Opt Rheumatol 2015; 1(2): 239-54.
[http://dx.doi.org/10.1007/s40674-015-0022-7]
[5]
Conti A, Peccerillo F, Amerio P, et al. Efficacy and safety of switching to ixekizumab in secukinumab nonresponder psoriatic patients: Results from a multicenter experience. 2019; 180(6): 1547-8.
[6]
van de Kerkhof PCM, Griffiths CEM, Reich K, et al. Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol 2016; 75(1): 83-98.e4.
[http://dx.doi.org/10.1016/j.jaad.2016.03.024] [PMID: 27180926]
[7]
Georgakopoulos JR, Phung M, Ighani A, Yeung J. Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapies. J Am Acad Dermatol 2018; 79(1): 155-7.
[http://dx.doi.org/10.1016/j.jaad.2018.01.003] [PMID: 29307635]
[8]
Mease P, McInnes IB. Secukinumab: A new treatment option for psoriatic arthritis. Rheumatol Ther 2016; 3(1): 5-29.
[http://dx.doi.org/10.1007/s40744-016-0031-5] [PMID: 27747518]
[9]
Frieder J, Kivelevitch D, Menter A. Secukinumab: A review of the anti-IL-17A biologic for the treatment of psoriasis. Ther Adv Chronic Dis 2018; 9(1): 5-21.
[http://dx.doi.org/10.1177/2040622317738910] [PMID: 29344327]
[10]
Rhoden EL, Telo C, Sogari PR, Souto CAV. The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. Int J Impotence Res 2002; 14(4): 245-50.
[11]
Semet M, Paci M, Saïas-Magnan J, et al. The impact of drugs on male fertility: A review. Andrology 2017; 5(4): 640-63.
[http://dx.doi.org/10.1111/andr.12366] [PMID: 28622464]
[12]
Blauvelt A, Reich K, Mehlis S, et al. Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study. J Eur Acad Dermatol Venereol 2017; 31(10): 1693-9.
[http://dx.doi.org/10.1111/jdv.14391] [PMID: 28602039]
[13]
Ryan C, Sadlier M, De Vol E, et al. Genital psoriasis is associated with significant impairment in quality of life and sexual functioning. J Am Acad Dermatol 2015; 72(6): 978-83.
[http://dx.doi.org/10.1016/j.jaad.2015.02.1127] [PMID: 25824273]
[14]
Warren RB, Brnabic A, Saure D, et al. Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab. Br J Dermatol 2018; 178(5): 1064-71.
[http://dx.doi.org/10.1111/bjd.16140] [PMID: 29171861]
[15]
Paul C. Ixekizumab or secukinumab in psoriasis: What difference does it make? Br J Dermatol 2018; 178(5): 1003-5.
[http://dx.doi.org/10.1111/bjd.16497] [PMID: 29785816]
[16]
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30(2): 239-45.
[http://dx.doi.org/10.1038/clpt.1981.154] [PMID: 7249508]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 1
Year: 2020
Page: [69 - 72]
Pages: 4
DOI: 10.2174/1574886314666190726155147

Article Metrics

PDF: 29
HTML: 3